Alpha DNA Investment Management LLC Acquires 92 Shares of Johnson & Johnson (NYSE:JNJ)

Alpha DNA Investment Management LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,706 shares of the company’s stock after acquiring an additional 92 shares during the period. Alpha DNA Investment Management LLC’s holdings in Johnson & Johnson were worth $970,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the business. Tobias Financial Advisors Inc. boosted its position in shares of Johnson & Johnson by 9.1% in the 4th quarter. Tobias Financial Advisors Inc. now owns 4,941 shares of the company’s stock worth $715,000 after purchasing an additional 412 shares in the last quarter. Canada Pension Plan Investment Board raised its stake in Johnson & Johnson by 6.7% during the fourth quarter. Canada Pension Plan Investment Board now owns 4,528,010 shares of the company’s stock valued at $654,841,000 after buying an additional 283,544 shares during the last quarter. GKV Capital Management Co. Inc. bought a new stake in Johnson & Johnson in the fourth quarter worth $506,000. First Commonwealth Financial Corp PA grew its stake in shares of Johnson & Johnson by 13.7% in the fourth quarter. First Commonwealth Financial Corp PA now owns 9,922 shares of the company’s stock worth $1,435,000 after acquiring an additional 1,198 shares during the last quarter. Finally, Capital Square LLC increased its holdings in shares of Johnson & Johnson by 16.9% during the fourth quarter. Capital Square LLC now owns 5,868 shares of the company’s stock valued at $862,000 after acquiring an additional 848 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on JNJ shares. Stifel Nicolaus dropped their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Bank of America cut their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a report on Thursday, April 10th. Sanford C. Bernstein restated a “market perform” rating on shares of Johnson & Johnson in a report on Wednesday. Leerink Partners cut their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Finally, Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Nine analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $171.72.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 2.3 %

Shares of Johnson & Johnson stock opened at $157.42 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a market capitalization of $379.37 billion, a PE ratio of 23.67, a P/E/G ratio of 2.56 and a beta of 0.49. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company’s fifty day simple moving average is $159.47 and its 200-day simple moving average is $155.06.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date is Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.30%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.